{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T01:25:06Z","timestamp":1773797106713,"version":"3.50.1"},"reference-count":45,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,6,30]],"date-time":"2017-06-30T00:00:00Z","timestamp":1498780800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","europeanneuropsychopharmacology.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.euroneuro.2017.06.013","type":"journal-article","created":{"date-parts":[[2017,7,7]],"date-time":"2017-07-07T18:16:16Z","timestamp":1499451376000},"page":"865-876","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"title":["Lurasidone in combination with lithium or valproate for the maintenance treatment of bipolar I disorder"],"prefix":"10.1016","volume":"27","author":[{"given":"Joseph R.","family":"Calabrese","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrei","family":"Pikalov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Streicher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josephine","family":"Cucchiaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongcai","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antony","family":"Loebel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2017.06.013_bib1","unstructured":"American Psychiatric Association, 2000. Diagnostic and statistical manual of mental disorders (4th ed, text rev)."},{"key":"10.1016\/j.euroneuro.2017.06.013_bib2","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug-induced akathisia","volume":"154","author":"Barnes","year":"1989","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.06.013_bib3","doi-asserted-by":"crossref","first-page":"130","DOI":"10.4088\/JCP.09m05482yel","article-title":"Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial","volume":"71","author":"Bowden","year":"2010","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.06.013_bib4","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.clinthera.2015.11.013","article-title":"Lurasidone dose response in bipolar depression: a population dose-response analysis","volume":"38","author":"Chapel","year":"2016","journal-title":"Clin. Ther."},{"key":"10.1016\/j.euroneuro.2017.06.013_bib5","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/YIC.0b013e32835281ef","article-title":"Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study","volume":"27","author":"Citrome","year":"2012","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2017.06.013_bib6","first-page":"1","article-title":"Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study","author":"Citrome","year":"2013","journal-title":"CNS Spectr."},{"key":"10.1016\/j.euroneuro.2017.06.013_bib7","first-page":"321","article-title":"Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure","volume":"29","author":"Endicott","year":"1993","journal-title":"Psychopharmacol. Bull."},{"key":"10.1016\/j.euroneuro.2017.06.013_bib8","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1176\/ajp.152.11.1635","article-title":"Relapse and impairment in bipolar disorder","volume":"152","author":"Gitlin","year":"1995","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.06.013_bib9","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1177\/0269881116636545","article-title":"Evidence-based guidelines for treating bipolar disorder: revised third edition recommendations from the British Association for Psychopharmacology","volume":"30","author":"Goodwin","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2017.06.013_bib10","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3109\/15622975.2013.770551","article-title":"WFSBP Task Force on Treatment Guidelines for Bipolar Disorders. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder","volume":"14","author":"Grunze","year":"2013","journal-title":"World J. Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.06.013_bib11","unstructured":"Guy W., 1976. ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education, and Welfare publication (ADM) 76-338 Rockville, MD: National Institute of Mental Health; 1976."},{"key":"10.1016\/j.euroneuro.2017.06.013_bib12","unstructured":"Health Canada product monograph: \u3008http:\/\/www.sunovion.ca\/monographs\/latuda.pdf\u3009. (Accessed on 20 May 2017)."},{"key":"10.1016\/j.euroneuro.2017.06.013_bib14","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1399-5618.2011.00969.x","article-title":"Health-related quality of life in bipolar disorder","volume":"14","author":"IsHak","year":"2012","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.euroneuro.2017.06.013_bib15","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1046\/j.1399-5618.2003.00091.x","article-title":"A prospective, longitudinal study of percentage of time spent ill in patients with bipolar I or bipolar II disorders","volume":"6","author":"Joffe","year":"2004","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.euroneuro.2017.06.013_bib16","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1001\/archpsyc.59.6.530","article-title":"The long-term natural history of the weekly symptomatic status of bipolar I disorder","volume":"59","author":"Judd","year":"2002","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.06.013_bib17","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1001\/archpsyc.62.12.1322","article-title":"Psychosocial disability in the course of bipolar I and II disorders: a prospective, comparative, longitudinal study","volume":"62","author":"Judd","year":"2005","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.06.013_bib18","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/da.22479","article-title":"Lurasidone in the long-term treatment of patients with bipolar disorder: a 24-week open-label extension study","volume":"33","author":"Ketter","year":"2016","journal-title":"Depress. Anxiety."},{"key":"10.1016\/j.euroneuro.2017.06.013_bib20","unstructured":"Latuda US prescribing information: \u3008http:\/\/www.latuda.com\/LatudaPrescribingInformation.pdf\u3009. (Accessed on 20 May 2017)."},{"key":"10.1016\/j.euroneuro.2017.06.013_bib21","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.schres.2013.03.013","article-title":"Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: a 12-month, double-blind, noninferiority study","volume":"147","author":"Loebel","year":"2013","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2017.06.013_bib22","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.schres.2013.01.009","article-title":"Efficacy and safety of lurasidone 80 mg\/day and 160 mg\/day in the treatment of schizoprenia: a ramdomized, double-blind, placedo- and active-controlled trial","volume":"145","author":"Loebel","year":"2013","journal-title":"Schizophr. Res"},{"key":"10.1016\/j.euroneuro.2017.06.013_bib23","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1176\/appi.ajp.2013.13070984","article-title":"Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study","volume":"171","author":"Loebel","year":"2014","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.06.013_bib24","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1176\/appi.ajp.2013.13070985","article-title":"Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study","volume":"171","author":"Loebel","year":"2014","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.06.013_bib25","unstructured":"Lurasidone US Prescribing Information, 2014. \u3008http:\/\/www.latuda.com\/LatudaPrescribingInformation.pdf\u3009. (Accessed on 13 February 2016)."},{"key":"10.1016\/j.euroneuro.2017.06.013_bib26","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1111\/j.1399-5618.2009.00761.x","article-title":"A randomized, double-blind, placebo-controlled study of maintenance treatment with adjunctive risperidone long-acting therapy in patients with bipolar I disorder who relapse frequently","volume":"11","author":"Macfadden","year":"2009","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.euroneuro.2017.06.013_bib27","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1399-5618.2011.00898.x","article-title":"Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double-blind, randomized study","volume":"13","author":"Marcus","year":"2011","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.euroneuro.2017.06.013_bib29","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"132","author":"Montgomery","year":"1979","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.06.013_bib30","unstructured":"National Collaborating Centre for Mental Health, 2014. Bipolar Disorder: The Assessment and Management of Bipolar Disorder in Adults, Children and Young People in Primary and Secondary Care. Leicester UK: The British Psychological Society; The Royal College of Psychiatrists."},{"key":"10.1016\/j.euroneuro.2017.06.013_bib31","doi-asserted-by":"crossref","first-page":"920","DOI":"10.4088\/JCP.15cs09841","article-title":"Florida best practice psychotherapeutic medication guidelines for adults with bipolar disorder: a novel, practical, patient-centered guide for clinicians","volume":"77","author":"Ostacher","year":"2016","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.06.013_bib32","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.euroneuro.2015.04.007","article-title":"Hyperprolactinemia and medications for bipolar disorder: systematic review of a neglected issue in clinical practice","volume":"25","author":"Pacchiarotti","year":"2015","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2017.06.013_bib33","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1176\/appi.ajp.163.2.217","article-title":"Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)","volume":"163","author":"Perlis","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.06.013_bib34","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.euroneuro.2011.09.008","article-title":"Polarity index of pharmacologic agents used for maintenance treatment of bipolar disorder","volume":"22","author":"Popovich","year":"2012","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2017.06.013_bib35","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","article-title":"The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults","volume":"168","author":"Posner","year":"2011","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.06.013_bib36","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.biopsych.2010.01.015","article-title":"Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorder","volume":"68","author":"Quiroz","year":"2010","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.06.013_bib37","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0006-3223(02)01866-8","article-title":"The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression","volume":"54","author":"Rush","year":"2003","journal-title":"Biol. Psychiatry."},{"key":"10.1016\/j.euroneuro.2017.06.013_bib39","series-title":"The Anxiety Disease","author":"Sheehan","year":"1983"},{"key":"10.1016\/j.euroneuro.2017.06.013_bib40","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta. Psychiatr. Scand. Suppl."},{"key":"10.1016\/j.euroneuro.2017.06.013_bib41","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1176\/appi.ajp.2008.08020189","article-title":"Maintenance treatment for patients with bipolar I disorder: results from a North American study of quetiapine in combination with lithium or divalproex (trial 127)","volume":"166","author":"Suppes","year":"2009","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.06.013_bib43","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1176\/appi.ajp.160.12.2099","article-title":"The McLean-Harvard First-Episode Mania Study: prediction of recovery and first recurrence","volume":"160","author":"Tohen","year":"2003","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.06.013_bib44","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1192\/bjp.184.4.337","article-title":"Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone","volume":"184","author":"Tohen","year":"2004","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.06.013_bib45","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1016\/j.euroneuro.2015.07.013","article-title":"Recurrence rates in bipolar disorder: systematic comparison of long-term prospective, naturalistic studies versus randomized controlled trials","volume":"25","author":"V\u00e1zquez","year":"2015","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2017.06.013_bib46","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jad.2008.06.001","article-title":"Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126)","volume":"109","author":"Vieta","year":"2008","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2017.06.013_bib47","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/JCP.0b013e3181f15849","article-title":"Treatment options for bipolar depression: a systematic review of randomized, controlled trials","volume":"30","author":"Vieta","year":"2010","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2017.06.013_bib48","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1080\/15622970701530917","article-title":"A long-term prospective study on the outcome of bipolar patients treated with long-acting injectable risperidone","volume":"9","author":"Vieta","year":"2008","journal-title":"World J. Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.06.013_bib49","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.4088\/JCP.11m06878","article-title":"Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (Trial 144: a randomized controlled study)","volume":"72","author":"Weisler","year":"2011","journal-title":"J Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.06.013_bib51","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1192\/bjp.133.5.429","article-title":"A rating scale for mania: reliability, validity and sensitivity","volume":"133","author":"Young","year":"2011","journal-title":"Br. J. Psychiatry"}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X17302900?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X17302900?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,30]],"date-time":"2018-08-30T13:55:25Z","timestamp":1535637325000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X17302900"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":45,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S0924977X17302900"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2017.06.013","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lurasidone in combination with lithium or valproate for the maintenance treatment of bipolar I disorder","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2017.06.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}